A number of popular blue-chip ASX 200 shares recently hit 52-week lows or worse.
While this is disappointing, it could have created a buying opportunity for patient investors.
For example, listed below are three top blue-chips that analysts think are top buys:
Image source: Getty Images
Cochlear Ltd (ASX: COH)
The first blue-chip ASX 200 share that has fallen heavily is Cochlear.
The hearing implant leader recently reported a softer half-year result, with profit declining and margins coming under pressure. A key issue was a higher mix of lower-priced emerging market sales, which weighed on revenue growth despite solid unit growth.
In addition, the rollout of its new Nexa system has been slower than expected, delaying revenue growth and disrupting the earnings trajectory investors had been anticipating.
However, demand remains strong and the company has been gaining market share, with Nexa now making up the majority of units sold. This suggests the issue is more about timing than underlying demand.
In light of this, Cochlear's global leadership and exposure to long-term hearing healthcare demand could make the recent pullback an interesting opportunity for Aussie investors.
CSL Ltd (ASX: CSL)
Another blue-chip ASX 200 share that looks attractive after a heavy decline is CSL.
The biotech giant has faced pressure following a softer-than-expected result, with its key CSL Behring division weighing on performance. Margin recovery has been slower than hoped and earnings growth expectations have been revised lower.
Adding to the uncertainty is the recent CEO departure, which has raised questions around leadership and the company's near-term direction.
That said, CSL remains a global leader in plasma therapies with significant barriers to entry and strong long-term demand drivers.
For investors with a long-term horizon, the combination of quality and a lower share price could present a more balanced risk-reward opportunity.
Treasury Wine Estates Ltd (ASX: TWE)
A final blue-chip ASX 200 share that has come under significant pressure is Treasury Wine Estates.
Last month, the wine giant reported a sharp decline in earnings, with margins compressing and revenue falling amid softer conditions in key markets such as the United States and China. A large non-cash impairment also led to a statutory loss, while the interim dividend was suspended to preserve capital.
These developments highlight that the business is currently going through a period of transition rather than simply experiencing a short-term slowdown.
Management is now focused on its TWE Ascent transformation program, which aims to reduce costs, simplify operations, and reposition the portfolio for sustainable growth.
While there are clear execution risks, the company's portfolio of premium wine brands continues to perform in the market. If the transformation is successful, the current weakness could prove to be an incredible buying opportunity.
